GlassScriptPhysician profile
Steven Spires
NPI 1043453632
$2,798.72
in general payments reported to CMS, 2019-2025
17 companies · $677 in 2025
The $677 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.42 · 2022: $600 · 2023: $394 · 2024: $1,105 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,040 · Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,039.52 |
| Education | $135.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $600.00 | 2022 | |
| Melinta Therapeutics, LLC | $393.75 | 2023-2025 | Orbactiv, Kimyrsa, Rezzayo |
| Gilead Sciences, INC. | $376.50 | 2023-2025 | Biktarvy, Veklury |
| Paratek Pharmaceuticals, INC. | $216.76 | 2023-2025 | Nuzyra |
| Viiv Healthcare Company | $216.67 | 2023-2025 | Cabenuva, Dovato |
| Insmed, INC. | $176.23 | 2024-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $159.94 | 2024-2025 | Xembify |
| Merck Sharp & Dohme LLC | $156.25 | 2023-2025 | Dificid, Delstrigo, Zerbaxa |
| Abbvie INC. | $141.16 | 2023-2024 | Dalvance, Teflaro, Avycaz |
| Cumberland Pharmaceuticals, INC. | $117.83 | 2024-2025 | Vibativ |
| La Jolla Pharmaceutical Company | $117.07 | 2023-2025 | Xerava, Zevtera |
| Angiodynamics, INC. | $41.99 | 2025 | Angiovac |
| Tetraphase Pharmaceuticals, INC. | $23.42 | 2025 | |
| X4 Pharmaceuticals, INC. | $21.91 | 2025 | Xolremdi |
| Solventum Corporation | $15.82 | 2025 | V.A.C.Ulta |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $12.01 | 2019 | |
| Allergan, INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Spires listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.